doi: 10.1161/hs0402.105555
(Stroke. 2002;33:1077.)
© 2002 American Heart Association, Inc.
Original Contributions |
Albumin Therapy of Transient Focal Cerebral Ischemia
In Vivo Analysis of Dynamic Microvascular Responses
From the Cerebral Vascular Disease Research Center, Department of Neurology, University of Miami School of Medicine, Miami, Fla (L.B., Y.L., W.Z., R.B., M.D.G.); Laboratoire de Recherches Cérébrovasculaires, CNRS UPR 646, Université Paris 7, Paris, France (E.P., H.N., J.S.); and Department of Electrical and Computer Engineering, University of Miami College of Engineering, Coral Gables, Fla (P.R.).
Reprint requests to Ludmila Belayev, MD, Department of Neurology (D4-5), University of Miami School of Medicine, PO Box 016960, Miami, FL 33101. E-mail lbelayev{at}stroke.med.miami.edu
Background and Purpose— To study whether intravascular or hemodynamic factors contribute to the marked neuroprotective effect of albumin therapy in focal cerebral ischemia, 2 complementary methods were applied: laser-scanning confocal microscopy (LSCM) and laser-Doppler perfusion imaging (LDPI).
Methods— In the LSCM study, Sprague-Dawley rats were anesthetized with halothane/nitrous oxide, and a cranial window was placed over the dorsolateral frontoparietal cortex. Rats received 2-hour middle cerebral artery occlusion (MCAO) by an intraluminal suture and were treated with human albumin (1.25 g/kg; n=4) or saline (n=3) after 30 minutes of recirculation. Video images of cortical vessels were continually acquired and were digitized offline to measure diameters and fluorescent erythrocyte velocities. In the LDPI study, cortical perfusion was measured in anesthetized Sprague-Dawley rats that received 2-hour MCAO and were treated with albumin (2.5 g/kg; n=6) or saline (n=5) at 30 minutes after recirculation.
Results— In the LSCM study, MCAO was associated with arteriolar dilation and slowing of capillary and venular erythrocyte perfusion. During the first 15 to 30 minutes of postischemic recirculation, prominent foci of vascular stagnation developed within cortical venules, associated with thrombuslike foci and adherent corpuscular structures consistent in size with neutrophils. Saline administration failed to affect these phenomena, while albumin therapy was followed by significant increases in arteriolar diameter (
12%; P=0.007) and by a prompt improvement of venular and capillary erythrocyte perfusion and a partial disappearance of adherent thrombotic material. Albumin therapy increased erythrocyte flow velocity in both capillaries (288±73% versus 76±18% in the saline group; P=0.023) and venules (2.7-fold [P=0.001] versus 1.0-fold in the saline group [P=NS]). In the LDPI study, cortical perfusion declined during MCAO and rose initially with recirculation (to 135% of baseline) in both groups. Mean cortical perfusion improved slightly (14%; P=NS) in albumin-treated animals.
Conclusions— These results reveal a beneficial effect of albumin therapy in reversing stagnation, thrombosis, and corpuscular adherence within cortical venules in the reperfusion phase after focal ischemia and support its utility in the treatment of acute ischemic stroke.
Key Words: albumin • middle cerebral artery occlusion • neuroprotection • perfusion • rats
This article has been cited by other articles:
 |
|
 |
|
  H.-P. Park, A. Nimmagadda, R. A. DeFazio, R. Busto, R. Prado, and M. D. Ginsberg Albumin Therapy Augments the Effect of Thrombolysis on Local Vascular Dynamics in a Rat Model of Arteriolar Thrombosis: A Two-Photon Laser-Scanning Microscopy Study Stroke, May 1, 2008; 39(5): 1556 - 1562. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Nimmagadda, H.-P. Park, R. Prado, and M. D. Ginsberg Albumin Therapy Improves Local Vascular Dynamics in a Rat Model of Primary Microvascular Thrombosis: A Two-Photon Laser-Scanning Microscopy Study Stroke, January 1, 2008; 39(1): 198 - 204. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. D. Ginsberg Life After Cerovive: A Personal Perspective on Ischemic Neuroprotection in the Post-NXY-059 Era Stroke, June 1, 2007; 38(6): 1967 - 1972. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. P. Adams Jr, G. del Zoppo, M. J. Alberts, D. L. Bhatt, L. Brass, A. Furlan, R. L. Grubb, R. T. Higashida, E. C. Jauch, C. Kidwell, et al. Guidelines for the Early Management of Adults With Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Circulation, May 22, 2007; 115(20): e478 - e534. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. P. Adams Jr, G. del Zoppo, M. J. Alberts, D. L. Bhatt, L. Brass, A. Furlan, R. L. Grubb, R. T. Higashida, E. C. Jauch, C. Kidwell, et al. Guidelines for the Early Management of Adults With Ischemic Stroke: A Guideline From the American Heart Association/ American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists Stroke, May 1, 2007; 38(5): 1655 - 1711. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. D. Ginsberg, M. D. Hill, Y. Y. Palesch, K. J. Ryckborst, and D. Tamariz The ALIAS Pilot Trial: A Dose-Escalation and Safety Study of Albumin Therapy for Acute Ischemic Stroke--I: Physiological Responses and Safety Results Stroke, August 1, 2006; 37(8): 2100 - 2106. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Y. Palesch, M. D. Hill, K. J. Ryckborst, D. Tamariz, and M. D. Ginsberg The ALIAS Pilot Trial: A Dose-Escalation and Safety Study of Albumin Therapy for Acute Ischemic Stroke--II: Neurologic Outcome and Efficacy Analysis Stroke, August 1, 2006; 37(8): 2107 - 2114. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Belayev, I. Saul, R. Busto, K. Danielyan, A. Vigdorchik, L. Khoutorova, and M. D. Ginsberg Albumin Treatment Reduces Neurological Deficit and Protects Blood-Brain Barrier Integrity After Acute Intracortical Hematoma in the Rat Stroke, February 1, 2005; 36(2): 326 - 331. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Belayev, V. L. Marcheselli, L. Khoutorova, E. B. Rodriguez de Turco, R. Busto, M. D. Ginsberg, and N. G. Bazan Docosahexaenoic Acid Complexed to Albumin Elicits High-Grade Ischemic Neuroprotection Stroke, January 1, 2005; 36(1): 118 - 123. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Evidence-based Colloid Use in the Critically Ill: American Thoracic Society Consensus Statement Am. J. Respir. Crit. Care Med., December 1, 2004; 170(11): 1247 - 1259. [Full Text] [PDF]
|
|
|
|
|
|
R. C. Seet, E. C. Lim, B. P. Chan, B. K. Ong, and T. Dziedzic Serum Albumin Level as a Predictor of Ischemic Stroke Outcome Stroke, November 1, 2004; 35(11): 2435 - 2436. [Full Text] [PDF]
|
|
|
|
|
|
T. Dziedzic, A. Slowik, and A. Szczudlik Serum Albumin Level as a Predictor of Ischemic Stroke Outcome Stroke, June 1, 2004; 35(6): e156 - e158. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. T. Gum, R. A. Swanson, C. Alano, J. Liu, S. Hong, P. R. Weinstein, and S. S. Panter Human Serum Albumin and its N-Terminal Tetrapeptide (DAHK) Block Oxidant-Induced Neuronal Death Stroke, February 1, 2004; 35(2): 590 - 595. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E.-M. Muchitsch, H. P. Schwarz, M. D. Ginsberg, L. Belayev, and R. Busto Beneficial Effect of Albumin Therapy Attributable to {alpha}1-Acid Glycoprotein? Stroke, January 1, 2003; 34(1): 4 - 5. [Full Text] [PDF]
|
|
|
|
|
|
M. D. Ginsberg Adventures in the Pathophysiology of Brain Ischemia: Penumbra, Gene Expression, Neuroprotection: The 2002 Thomas Willis Lecture Stroke, January 1, 2003; 34(1): 214 - 223. [Abstract] [Full Text] [PDF]
|
|